Oxford BioDynamics Plc has appointed Dr. Steven Arrivo as Senior Vice President of Business and Corporate Development. Dr. Arrivo brings over 20 years of science and industry experience along with an established track record in business and corporate development within personalized medicine across big pharma, biotech and molecular diagnostics companies. Dr. Arrivo joins Oxford BioDynamics from CellCarta Biosciences (formerly Caprion) where he spent five years in Business Development, as Senior Director and Vice President.

Prior to that he was at Biodesix and Ventana Medical Systems. Before then, he spent four years at Pfizer in various R&D roles and he began his career at Merck & Co. Inc. as a Senior Project Scientist following several academic research positions. Dr. Arrivo holds a Bachelor's degree in Chemistry from the University of Eastern Illinois, and a Master's degree in Synthetic Organic and Inorganic Chemistry and Ph.D. in Physical Chemistry from Northwestern University.

He completed Postdoctoral studies in Physical Chemistry at Columbia University. At the company, Dr. Arrivo's role will be to implement effective marketing and sales strategies for the newly launched EpiSwitch® PSE prostate cancer detection test. His specific focus will be to grow sales in the US market, where he has considerable experience of launching products.